nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—Wound—Cyclosporine—focal segmental glomerulosclerosis	0.083	0.18	CcSEcCtD
Dabigatran etexilate—F2—endothelium—focal segmental glomerulosclerosis	0.0733	0.188	CbGeAlD
Dabigatran etexilate—UGT1A9—kidney—focal segmental glomerulosclerosis	0.0408	0.105	CbGeAlD
Dabigatran etexilate—CES2—nephron tubule—focal segmental glomerulosclerosis	0.0374	0.096	CbGeAlD
Dabigatran etexilate—NQO2—nephron tubule—focal segmental glomerulosclerosis	0.0334	0.0857	CbGeAlD
Dabigatran etexilate—UGT2B7—kidney—focal segmental glomerulosclerosis	0.0329	0.0843	CbGeAlD
Dabigatran etexilate—CES2—kidney—focal segmental glomerulosclerosis	0.0329	0.0843	CbGeAlD
Dabigatran etexilate—CES2—cortex of kidney—focal segmental glomerulosclerosis	0.032	0.0821	CbGeAlD
Dabigatran etexilate—F2—kidney—focal segmental glomerulosclerosis	0.0295	0.0756	CbGeAlD
Dabigatran etexilate—NQO2—kidney—focal segmental glomerulosclerosis	0.0294	0.0754	CbGeAlD
Dabigatran etexilate—NQO2—cortex of kidney—focal segmental glomerulosclerosis	0.0286	0.0734	CbGeAlD
Dabigatran etexilate—Thrombosis—Cyclosporine—focal segmental glomerulosclerosis	0.017	0.0368	CcSEcCtD
Dabigatran etexilate—Rectal haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.0133	0.0289	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0132	0.0287	CcSEcCtD
Dabigatran etexilate—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.0129	0.0279	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.011	0.0238	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.01	0.0216	CcSEcCtD
Dabigatran etexilate—F2—PAR4-mediated thrombin signaling events—GNAQ—focal segmental glomerulosclerosis	0.00966	0.0652	CbGpPWpGaD
Dabigatran etexilate—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00895	0.0194	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00874	0.0189	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00798	0.0173	CcSEcCtD
Dabigatran etexilate—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00773	0.0167	CcSEcCtD
Dabigatran etexilate—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.00755	0.0164	CcSEcCtD
Dabigatran etexilate—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.00743	0.0161	CcSEcCtD
Dabigatran etexilate—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00726	0.0157	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00724	0.0157	CcSEcCtD
Dabigatran etexilate—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.00722	0.0185	CbGeAlD
Dabigatran etexilate—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00702	0.0152	CcSEcCtD
Dabigatran etexilate—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.00677	0.0147	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00673	0.0146	CcSEcCtD
Dabigatran etexilate—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00673	0.0146	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00664	0.0144	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.0066	0.0143	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00655	0.0142	CcSEcCtD
Dabigatran etexilate—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00642	0.0139	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00637	0.0138	CcSEcCtD
Dabigatran etexilate—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00635	0.0138	CcSEcCtD
Dabigatran etexilate—ABCB1—kidney—focal segmental glomerulosclerosis	0.00634	0.0163	CbGeAlD
Dabigatran etexilate—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00632	0.0137	CcSEcCtD
Dabigatran etexilate—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.00618	0.0158	CbGeAlD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—ANGPT2—focal segmental glomerulosclerosis	0.00615	0.0415	CbGpPWpGaD
Dabigatran etexilate—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00608	0.0132	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00605	0.0131	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00597	0.0129	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00594	0.0129	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00593	0.0128	CcSEcCtD
Dabigatran etexilate—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00548	0.0119	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00545	0.0118	CcSEcCtD
Dabigatran etexilate—F2—Thrombin signalling through proteinase activated receptors (PARs)—GNAQ—focal segmental glomerulosclerosis	0.00527	0.0355	CbGpPWpGaD
Dabigatran etexilate—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00526	0.0114	CcSEcCtD
Dabigatran etexilate—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00519	0.0112	CcSEcCtD
Dabigatran etexilate—F2—PAR1-mediated thrombin signaling events—TRPC6—focal segmental glomerulosclerosis	0.00497	0.0336	CbGpPWpGaD
Dabigatran etexilate—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00486	0.0105	CcSEcCtD
Dabigatran etexilate—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.00481	0.0104	CcSEcCtD
Dabigatran etexilate—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00459	0.00994	CcSEcCtD
Dabigatran etexilate—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00454	0.00984	CcSEcCtD
Dabigatran etexilate—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00448	0.0097	CcSEcCtD
Dabigatran etexilate—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00448	0.0097	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00445	0.00963	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—MYH10—focal segmental glomerulosclerosis	0.00436	0.0294	CbGpPWpGaD
Dabigatran etexilate—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.00429	0.0093	CcSEcCtD
Dabigatran etexilate—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00427	0.00924	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00421	0.00912	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00421	0.0091	CcSEcCtD
Dabigatran etexilate—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00417	0.00903	CcSEcCtD
Dabigatran etexilate—F2—PAR1-mediated thrombin signaling events—GNAQ—focal segmental glomerulosclerosis	0.00416	0.0281	CbGpPWpGaD
Dabigatran etexilate—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00391	0.00847	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.00383	0.00829	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00378	0.00818	CcSEcCtD
Dabigatran etexilate—F2—Regulation of IGF Activity by IGFBP—MMP2—focal segmental glomerulosclerosis	0.00372	0.0251	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.00371	0.0251	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00371	0.00803	CcSEcCtD
Dabigatran etexilate—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.0037	0.00802	CcSEcCtD
Dabigatran etexilate—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.00367	0.00795	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—ANGPT2—focal segmental glomerulosclerosis	0.00356	0.024	CbGpPWpGaD
Dabigatran etexilate—F2—Blood Clotting Cascade—SERPINE1—focal segmental glomerulosclerosis	0.00352	0.0237	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00351	0.0076	CcSEcCtD
Dabigatran etexilate—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.00341	0.00739	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.0034	0.00735	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—AGTR1—focal segmental glomerulosclerosis	0.00337	0.0227	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00316	0.00685	CcSEcCtD
Dabigatran etexilate—F2—Syndecan-4-mediated signaling events—FN1—focal segmental glomerulosclerosis	0.00313	0.0211	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00308	0.00667	CcSEcCtD
Dabigatran etexilate—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00304	0.00658	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00294	0.00636	CcSEcCtD
Dabigatran etexilate—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00284	0.00615	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	0.0028	0.0189	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—FN1—focal segmental glomerulosclerosis	0.00279	0.0188	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00273	0.00591	CcSEcCtD
Dabigatran etexilate—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00271	0.00586	CcSEcCtD
Dabigatran etexilate—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00271	0.00586	CcSEcCtD
Dabigatran etexilate—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00269	0.00582	CcSEcCtD
Dabigatran etexilate—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00255	0.00552	CcSEcCtD
Dabigatran etexilate—F2—IL1 and megakaryotyces in obesity—MMP9—focal segmental glomerulosclerosis	0.00251	0.017	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—FN1—focal segmental glomerulosclerosis	0.00219	0.0148	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.00219	0.0148	CbGpPWpGaD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—ALB—focal segmental glomerulosclerosis	0.00202	0.0136	CbGpPWpGaD
Dabigatran etexilate—F2—Syndecan-4-mediated signaling events—MMP9—focal segmental glomerulosclerosis	0.002	0.0135	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—MMP2—focal segmental glomerulosclerosis	0.00186	0.0125	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—SERPINE1—focal segmental glomerulosclerosis	0.0018	0.0121	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—ALB—focal segmental glomerulosclerosis	0.00179	0.0121	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—CTGF—focal segmental glomerulosclerosis	0.00161	0.0109	CbGpPWpGaD
Dabigatran etexilate—F2—Complement and Coagulation Cascades—SERPINE1—focal segmental glomerulosclerosis	0.0016	0.0108	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—focal segmental glomerulosclerosis	0.00158	0.0107	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.00153	0.0104	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.00151	0.0102	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—SERPINE1—focal segmental glomerulosclerosis	0.00146	0.00986	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—ALB—focal segmental glomerulosclerosis	0.00146	0.00984	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ACTN4—focal segmental glomerulosclerosis	0.00144	0.00974	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.00137	0.00926	CbGpPWpGaD
Dabigatran etexilate—CES2—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.00135	0.00908	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	0.00134	0.00906	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.00128	0.00866	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—FN1—focal segmental glomerulosclerosis	0.00127	0.00856	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.00117	0.00792	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	0.00116	0.00783	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—AGTR1—focal segmental glomerulosclerosis	0.00116	0.00782	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—ALB—focal segmental glomerulosclerosis	0.00116	0.00782	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.00115	0.00774	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	0.00112	0.00758	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—focal segmental glomerulosclerosis	0.00109	0.00734	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.00105	0.00708	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00101	0.00682	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.000995	0.00671	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.000982	0.00663	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	0.000966	0.00652	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—AGT—focal segmental glomerulosclerosis	0.000957	0.00646	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—focal segmental glomerulosclerosis	0.000936	0.00632	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	0.000933	0.00629	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.000919	0.0062	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—FN1—focal segmental glomerulosclerosis	0.000915	0.00618	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.00089	0.006	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.000826	0.00557	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.000815	0.0055	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—AGTR1—focal segmental glomerulosclerosis	0.000813	0.00549	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—EDN1—focal segmental glomerulosclerosis	0.000796	0.00537	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000793	0.00535	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000777	0.00524	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00077	0.00519	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.000739	0.00498	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TRPC6—focal segmental glomerulosclerosis	0.000692	0.00467	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CD40LG—focal segmental glomerulosclerosis	0.000681	0.0046	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	0.000668	0.0045	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000659	0.00445	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—focal segmental glomerulosclerosis	0.000645	0.00435	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000607	0.00409	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	0.000603	0.00407	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000592	0.004	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000592	0.00399	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—GNAQ—focal segmental glomerulosclerosis	0.000579	0.0039	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	0.000555	0.00375	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—ALB—focal segmental glomerulosclerosis	0.000554	0.00374	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000547	0.00369	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000521	0.00352	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.000508	0.00343	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000502	0.00339	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000492	0.00332	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.00048	0.00324	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—ACE—focal segmental glomerulosclerosis	0.000462	0.00312	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000456	0.00307	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000437	0.00295	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000435	0.00294	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000433	0.00292	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000416	0.00281	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000411	0.00277	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000397	0.00268	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000395	0.00267	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000378	0.00255	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.00037	0.0025	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000366	0.00247	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—LPL—focal segmental glomerulosclerosis	0.000361	0.00244	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	0.000351	0.00237	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—FN1—focal segmental glomerulosclerosis	0.000344	0.00232	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NOS2—focal segmental glomerulosclerosis	0.00034	0.00229	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000334	0.00226	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000332	0.00224	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000319	0.00215	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AGT—focal segmental glomerulosclerosis	0.000309	0.00209	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000307	0.00207	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000304	0.00205	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.0003	0.00203	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—AGT—focal segmental glomerulosclerosis	0.000293	0.00198	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	0.000286	0.00193	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ALB—focal segmental glomerulosclerosis	0.000286	0.00193	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000284	0.00191	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	0.000278	0.00187	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—LIPC—focal segmental glomerulosclerosis	0.00027	0.00182	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000257	0.00174	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.000257	0.00173	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000237	0.0016	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ALB—focal segmental glomerulosclerosis	0.000237	0.0016	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000235	0.00159	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000235	0.00158	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000233	0.00157	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—MMP2—focal segmental glomerulosclerosis	0.00023	0.00155	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000219	0.00148	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000219	0.00148	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000214	0.00144	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000208	0.00141	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	0.000197	0.00133	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000196	0.00132	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000193	0.0013	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TGFB1—focal segmental glomerulosclerosis	0.000181	0.00122	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000179	0.00121	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000178	0.0012	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—LPL—focal segmental glomerulosclerosis	0.000165	0.00111	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000152	0.00103	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000148	0.000996	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AGT—focal segmental glomerulosclerosis	0.000141	0.00095	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.00014	0.000943	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	0.000137	0.000925	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—LPL—focal segmental glomerulosclerosis	0.000134	0.000903	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000126	0.000852	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000117	0.000787	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AGT—focal segmental glomerulosclerosis	0.000114	0.000772	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALB—focal segmental glomerulosclerosis	0.000108	0.000729	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000101	0.000679	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	9.71e-05	0.000655	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	8.85e-05	0.000597	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALB—focal segmental glomerulosclerosis	8.78e-05	0.000593	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	8.6e-05	0.00058	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	8.16e-05	0.00055	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.44e-05	0.000502	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	6.14e-05	0.000414	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.13e-05	0.000414	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	5.25e-05	0.000354	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	4.03e-05	0.000272	CbGpPWpGaD
